Kyntra Bio profit margin KYNB

Gross, operating and net profit as a share of revenue over the last twelve months, from 2014.

Net margin, 12 months: n/m; a quarter missing
Peer median: 9.2%

Kyntra Bio's net margin over the last twelve months can't be worked out yet: a quarter of its results is missing from our data.

Profit margin over time

GrossOperatingNet

Open the interactive chart, with overlays and comparisons

Fiscal year by fiscal year

Fiscal year	Net margin	Operating margin	Gross margin
FY2025	n/a	n/a	n/a
FY2024	n/a	n/a	n/a
FY2023	n/a	n/a	87.2%
FY2022	n/a	n/a	85.6%
FY2021	n/a	n/a	94.5%
FY2020	n/a	n/a	95.0%
FY2019	−30.0%	−34.8%	99.6%
FY2018	−40.6%	−40.7%	n/a
FY2017	−92.3%	−89.5%	n/a
FY2016	−34.3%	−29.9%	n/a
FY2015	−47.4%	−42.9%	n/a
FY2014	−43.2%	−36.4%	n/a

Quarter by quarter

Quarter	Ended	Net margin, 12 months	Change on a year
Q2 FY26	Jun 30, 2026	n/a	n/a
Q1 FY26	Mar 31, 2026	n/a	n/a
Q4 FY25	Dec 31, 2025	n/a	n/a
Q3 FY25	Sep 30, 2025	n/a	n/a
Q2 FY25	Jun 30, 2025	n/a	n/a
Q1 FY25	Mar 31, 2025	n/a	n/a
Q4 FY24	Dec 31, 2024	n/a	n/a
Q3 FY24	Sep 30, 2024	n/a	n/a
Q2 FY24	Jun 30, 2024	n/a	n/a
Q1 FY24	Mar 31, 2024	n/a	n/a
Q4 FY23	Dec 31, 2023	n/a	n/a
Q3 FY23	Sep 30, 2023	n/a	n/a

Against its peers

Companies in Drug Manufacturers - General nearest Kyntra Bio's size, closest first, today.

Company	Profit margin
KYNBKyntra Bio	n/m
ATNMActinium Pharmaceuticals	n/m
SPROSpero Therapeutics	15.7%
LFVNLifevantage	2.8%
Peer median	9.2%

What the profit margin tells you

Profit as a share of revenue at three levels: gross (after making the product), operating (after running the business) and net (after everything, including tax and interest).

Compare within an industry. 10% is superb for a retailer and poor for a software company.

More on Kyntra Bio

Valuation data, not investment advice. Prices as of Oct 23, 2026. Reported figures come from the company's filings with the SEC.